scholarly journals BK Polyomavirus‐Specific 9mer CD 8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study

2017 ◽  
Vol 17 (10) ◽  
pp. 2591-2600 ◽  
Author(s):  
C. Leboeuf ◽  
S. Wilk ◽  
R. Achermann ◽  
I. Binet ◽  
D. Golshayan ◽  
...  
Keyword(s):  
Cohort Study ◽  
T Cell ◽  
Kidney Transplant ◽  
T Cell Responses ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
First Report ◽  
Cell Responses ◽  
Bk Polyomavirus

scholarly journals Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nathalie Chavarot ◽  
Amani Ouedrani ◽  
Olivier Marion ◽  
Marianne Leruez-Ville ◽  
Estelle Villain ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
T Cell Responses ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Responses

scholarly journals Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

2008 ◽  
Vol 6 (1) ◽  
pp. 29 ◽  
Author(s):  
Adrian Egli ◽  
Isabelle Binet ◽  
Simone Binggeli ◽  
Clemens Jäger ◽  
Alexis Dumoulin ◽  
...  
Keyword(s):  
T Cell ◽  
Viral Replication ◽  
Kidney Transplant ◽  
T Cell Responses ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Cell Responses

scholarly journals Skewed T cell responses to Epstein-Barr virus in long-term asymptomatic kidney transplant recipients

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0224211
Author(s):  
Cecilia Nakid-Cordero ◽  
Nadia Arzouk ◽  
Nicolas Gauthier ◽  
Nadine Tarantino ◽  
Martin Larsen ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
Epstein Barr Virus ◽  
T Cell Responses ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Barr Virus ◽  
Cell Responses ◽  
Epstein Barr

scholarly journals Comparison of humoral and cellular responses in kidney transplant recipients receiving BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines

2021 ◽  
Author(s):  
Maria Prendecki ◽  
Tina Thomson ◽  
Candice L Clarke ◽  
Paul Martin ◽  
Sarah Gleeson ◽  
...  
Keyword(s):  
T Cell ◽  
Kidney Transplant ◽  
T Cell Responses ◽  
Cellular Responses ◽  
Control Group ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Cell Responses ◽  
Transplant Patients ◽  
Kidney Transplant Patients

Background Attenuated immune responses to mRNA SARS-CoV-2 vaccines have been reported in solid organ transplant recipients. Most studies have assessed serological responses alone, and there is limited immunological data on vector-based vaccines in this population. This study compares the immunogenicity of BNT162b2 with ChAdOx1 in kidney transplant patients, assessing both serological and cellular responses. Methods 920 patients were screened for spike protein antibodies (anti-S) following 2 doses of either BNT162b2 (n=490) or ChAdOx1 (n=430). 106 patients underwent assessment with T-cell ELISpot assays. 65 health care workers were used as a control group. Results Anti-S was detected in 569 (61.8%) patients. Seroconversion rates in infection-naïve patients who received BNT162b2 were higher compared with ChAdOx1, at 269/410 (65.6%) and 156/358 (43.6%) respectively, p<0.0001. Anti-S concentrations were higher following BNT162b, 58(7.1-722) BAU/ml, compared with ChAdOx1, 7.1(7.1-39) BAU/ml, p<0.0001. Calcineurin inhibitor monotherapy, vaccination occurring >1st year post-transplant and receiving BNT162b2 was associated with seroconversion. Only 28/106 (26.4%) of patients had detectable T-cell responses. There was no difference in detection between infection-naïve patients who received BNT162b2, 7/40 (17.5%), versus ChAdOx1, 2/39 (5.1%), p=0.15. There was also no difference in patients with prior infection who received BNT162b2, 8/11 (72.7%), compared with ChAdOx1, 11/16 (68.8%), p=0.83. Conclusions. Enhanced humoral responses were seen with BNT162b2 compared with ChAdOx1 in kidney transplant patients. T-cell responses to both vaccines were markedly attenuated. Clinical efficacy data is still required but immunogenicity data suggests weakened responses to both vaccines in transplant patients, with ChAdOx1 less immunogenic compared with BNT162b2.

BK Polyomavirus–Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination

2020 ◽  
Author(s):  
Maud Wilhelm ◽  
Amandeep Kaur ◽  
Marion Wernli ◽  
Hans H Hirsch
Keyword(s):  
T Cells ◽  
T Cell ◽  
Kidney Transplant ◽  
Cd8 T Cells ◽  
Cd4 T Cells ◽  
T Cell Responses ◽  
Cd8 T Cell ◽  
Cell Responses ◽  
Bk Polyomavirus

Abstract Background BK polyomavirus (BKPyV) remains a significant cause of premature kidney transplant failure. In the absence of effective antivirals, current treatments rely on reducing immunosuppression to regain immune control over BKPyV replication. Increasing BKPyV-specific CD8 T cells correlate with clearance of BKPyV DNAemia in kidney transplant patients. We characterized a novel approach for expanding BKPyV-specific CD8 T cells in vitro using 27mer-long synthetic BKPyV peptides, different types of antigen-presenting cells, and CD4 T cells. Methods Langerhans cells and immature or mature monocyte-derived dendritic cells (Mo-DCs) were generated from peripheral blood mononuclear cells of healthy blood donors, pulsed with synthetic peptide pools consisting of 36 overlapping 27mers (27mP) or 180 15mers (15mP). BKPyV-specific CD8 T-cell responses were assessed by cytokine release assays using 15mP or immunodominant 9mers. Results BKPyV-specific CD8 T cells expanded using 27mP and required mature Mo-DCs (P = .0312) and CD4 T cells (P = .0156) for highest responses. The resulting BKPyV-specific CD8 T cells proliferated, secreted multiple cytokines including interferon γ and tumor necrosis factor α, and were functional (CD107a+/PD1–) and cytotoxic. Conclusions Synthetic 27mP permit expanding BKPyV-specific CD8 T-cell responses when pulsing mature Mo-DCs in presence of CD4 T cells, suggesting novel and safe approaches to vaccination and adoptive T-cell therapies for patients before and after kidney transplantation.

Sign in / Sign up

Export Citation Format

Share Document